Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
WithdrawnNCT01234298
Official study titleA Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Low- and High-dose Range Groups of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia
This study was withdrawn before enrollment.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Shire
TerminatedNCT01760889
Official study titleA Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia
This study ended early.
Multiple locations, including Miami SpringsSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Shire
CompletedNCT00484302
About this title
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
Read the official source — NCT00484302Official study titleCannabis and Psychosis. Randomized Clinical Trial: Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
This study has finished and is no longer accepting participants.
In CopenhagenSchizophrenia, AddictionBehavioural studyAges 18–35
- Countries
- Denmark
- Sponsor
- Bispebjerg Hospital
TerminatedNCT00364429
Official study titleInvestigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study
This study ended early.
In BarcelonaSchizophreniaMedication studyAges 18–45
- Countries
- Spain
- Sponsor
- GlaxoSmithKline
CompletedNCT00919620
About this title
Stage-specific Case Management for Early Psychosis
Read the official source — NCT00919620Official study titleOutcome of Stage-specific Early Intervention for Psychosis in Hong Kong: A Randomized Controlled Study
This study has finished and is no longer accepting participants.
In Hong KongSchizophreniaBehavioural studyAges 26–55
- Countries
- China
- Sponsor
- The University of Hong Kong
CompletedNCT01731977
About this title
Strengths-Based Family Psychoeducation for Youth Psychosis
Read the official source — NCT01731977Official study titleEffectiveness of the Strengths-Based Family Psychoeducation for Youth Psychosis: Randomized Controlled Trial
This study has finished and is no longer accepting participants.
Multiple locations, including NagoyaSchizophreniaBehavioural studyAges 20–74
- Countries
- Japan
- Sponsor
- Nagoya City University
TerminatedNCT00366704
What is this study about?Researchers are comparing bifeprunox and risperidone to find out how the approaches affect body weight in people with schizophrenia.
This study ended early.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
TerminatedNCT00366327
What is this study about?Researchers are studying Bifeprunox, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
This study ended early.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–66
- Countries
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
WithdrawnNCT00768612
What is this study about?Researchers are comparing SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day and Risperidone 4mg/day to find out how the approaches affect psychotic symptoms in people with schizophrenia.
This study was withdrawn before enrollment.
Location not clearly listedSchizophreniaMedication studyAges 20–65
- Countries
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
WithdrawnNCT00781794
Official study titleA Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia
This study was withdrawn before enrollment.
Multiple locations, including GlendaleSchizophreniaMedication studyAges 18–55
- Countries
- United States, France
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
CompletedNCT03075657
Official study titleStudy of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In BhubaneswarSchizophreniaMedication studyAges 18–65
- Countries
- India
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
CompletedNCT00036114
About this title
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
Read the official source — NCT00036114Official study titleStudy of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
This study has finished and is no longer accepting participants.
Multiple locations, including TuscaloosaSchizophreniaMedication studyAges 55–95
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
